Urethritis Market Research Report- Global Forecast till 2027

Urethritis Market Information: By Type (Infective Urethritis (Non-Gonococcal, Gonococcal), Nonspecific Urethritis), By Diagnosis (Microbial Culture Tests), Drug Treatment (Pain Killers, Anti-Bacterial, Antivirals), By End User - Global Forecast Till 2027

ID: MRFR/Pharma/3368-HCR | | Region: Global | 110 pages

Market Synopsis of Global Urethritis Market


Market Scenario


Urethritis is an inflammation of the urethra, or the tube that carries urine. It shows various symptoms such as pain while urinating and an increased urge to urinate. Additionally, burning sensation while urinating, presence of blood in the semen or urine, frequent urge and discomfort while urinating, abnormal discharge from the vagina or penis, etc. are other common symptoms. Other serious manifestation of urethritis include damage to the reproductive system, pelvic inflammatory disease (PID), which can result in infertility, and others. The primary cause of urethritis is usually infection by bacteria, while viral infection for pre-existing sexually transmitted diseases being the secondary cause. Urethritis is also caused by mechanical or chemical damage to the urethra during treatment or catheterization. Urethritis should not be confused with urinary tract infection (UTI). Urethritis is an inflammation of the urethra, while a UTI is an infection of the urinary tract and both may have similar symptoms, but often require different treatment.


Females have a greater chance of developing urethritis than males because of the nearness of urethra to the anus, which increases the chance of microbial infection. Also men’s urethras is much longer than women’s. According to the Centers for Disease Control and Prevention (CDC), causative organisms associated with urethritis include Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Human papillomavirus (HPV),  Herpes simplex virus (HSV), and Cytomegalovirus (CMV) and others. According to Antimicrobe, Nongonococcal bacteria caused urethritis in approximately 4 million Americans in 2015 accounting for 80% of the cases. According to Department of Health, U.K., urethritis accounts for 0.005% of hospital consulting with a high 97% of hospital consulting for urethritis requiring hospital admission. Almost 20% of hospital admissions for urethritis requires an emergency.


Rising demand for the treatment due to growing population, increasing screening, rising number of geriatrics, rising safety and success of drug treatment, the extricating nature of the pain, and others are driving the growth of the market. However, complications of treatment such as side effects, emergence of bacterial resistance to antibiotics, cost of urethritis treatment, and others may hamper the market growth.


The global urethritis market is expected to reach USD 18.0 billion by 2023 at a CAGR of ~ 8.0 % during the forecast period 2017-2023.


Research Methodology
Urethritis Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


Intended Audience



  • Global Urethritis manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1          Global Urethritis Market by Drug Treatment, 2016 (%)
Global Urethritis Market


Segments


The global urethritis market has been segmented on the basis of types, diagnosis, drug treatment, and end user.


Based on the types, the market has been segmented as infective urethritis and nonspecific urethritis.


Based on the diagnosis, the market has been segmented as physical examination, microbial culture tests, and others.


Based on the drug treatment, the market has been segmented as pain killers, anti-bacterials, antivirals, and others.


Based on the end user, the market has been segmented as hospitals and clinics, research and academics, and others.


Regional Analysis


The Americas accounts for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada. Additionally, the greater number of hospitalization procedures due to greater healthcare penetration in the U.S. and Canada drives the urethritis market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates are adding fuel to the market growth. The consolidation of large healthcare players in the U.S. also leads the growth of the market due to increased  buying power of the healthcare players.


Europe is the second largest market in the world due to growing healthcare industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to the large pharmaceutical industry.


Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future urethritis market in the region.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.


Key Players in the Global Urethritis Market


some of the key players profiled in the report are F. Hoffmann-La Roche AG, GlaxoSmithKline, AbbVie, Johnson & Johnson, and Merck & Co., Eli Lilly and Company, Bristol-Myers Squibb Company, Bayer AG, and AstraZeneca plc., and others.


 


 



Frequently Asked Questions (FAQ) :


Urethritis market is projected to grow at an 8.0% CAGR between 2020- 2027.

The Americas is expected to dominate the urethritis market.

Urethritis market is predicted to touch USD 18.0 billion by 2023.

Extricating nature of pain and increasing screening are the key factors driving the urethritis market.

Key players profiled in the urethritis market include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co., Johnson & Johnson, AbbVie, GlaxoSmithKline, and F. Hoffmann-La Roche AG.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Urethritis Market, by Type

6.1 Introduction

6.2 Infective Urethritis

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Nonspecific Urethritis

6.3.1 Market Estimates & Forecast, 2020-2027

7. Global Urethritis Market, by Diagnosis

7.1 Introduction

7.2 Physical Examination

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Microbial Culture Tests

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Others

7.4.1 Market Estimates & Forecast, 2020-2027

8. Global Urethritis Market, by Drug Treatment

8.1 Introduction

8.2 Pain Killers

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Anti-Bacterial

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Antiviral

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Others

8.5.1 Market Estimates & Forecast, 2020-2027

9. Global Urethritis Market, by End User

9.1 Introduction

9.2 Hospitals and Clinics

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Research and Academics

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Others

9.4.1 Market Estimates & Forecast, 2020-2027

10. Global Urethritis Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 F. Hoffmann-La Roche AG

12.1.1 Overview

12.1.2 Product Overview

12.1.3 Financials

12.2 AstraZeneca plc.

12.2.1 Overview

12.2.2 Product Overview

12.2.3 Financials

12.2.4 Key Developments

12.3 GlaxoSmithKline

12.3.1 Overview

12.3.2 Product Overview

12.3.3 Financials

12.3.4 Key Development

12.4 Teva Pharmaceutical Industries

12.4.1 Overview

12.4.2 Product Overview

12.4.3 Financials

12.4.4 Key Development

12.5 Johnson & Johnson

12.5.1 Overview

12.5.2 Product Overview

12.5.3 Financials

12.5.4 Key Development

12.6 Eli Lilly and Company

12.6.1 Overview

12.6.2 Product Overview

12.6.3 Financials

12.6.4 Key Development

12.7 Bristol-Myers Squibb Company

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Development

12.8 Bayer AG

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Development

12.9 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Urethritis Industry

14 Appendix


List of Tables

TABLE 1 GLOBAL URETHRITIS MARKET, BY TYPES, 2020-2027 (USD MILLION)

TABLE 2 INFECTIVE URETHRITIS FOR URETHRITIS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 3 NONSPECIFIC URETHRITIS FOR URETHRITIS MARKET, BY REGION 2020-2027 (USD

MILLION)

TABLE 4 GLOBAL URETHRITIS MARKET, BY DRUG TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 PAIN KILLERS FOR URETHRITIS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 ANTI-BACTERIALS FOR URETHRITIS MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 7 ANTIVIRALS FOR URETHRITIS MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 8 OTHERS FOR URETHRITIS MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 9 GLOBAL URETHRITIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 10 PHYSICAL EXAMINATION FOR URETHRITIS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 11 MICROBIAL CULTURE TESTS FOR URETHRITIS MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 12 OTHERS FOR URETHRITIS MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 13 GLOBAL URETHRITIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 NORTH AMERICA URETHRITIS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 15 NORTH AMERICA URETHRITIS MARKET, BY TYPES 2020-2027 (USD MILLION)

TABLE 16 NORTH AMERICA URETHRITIS MARKET, BY DRUG TREATMENT 2020-2027 (USD MILLION)

TABLE 17 NORTH AMERICA URETHRITIS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 18 NORTH AMERICA URETHRITIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 NORTH AMERICA URETHRITIS MARKET BY REGION 2020-2027 (USD MILLION)

TABLE 20 EUROPE URETHRITIS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 21 EUROPE URETHRITIS MARKET, BY TYPES 2020-2027 (USD MILLION)

TABLE 22 EUROPE URETHRITIS MARKET, BY DRUG TREATMENT 2020-2027 (USD MILLION)

TABLE 23 EUROPE URETHRITIS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 24 EUROPE URETHRITIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EUROPE URETHRITIS MARKET BY REGION 2020-2027 (USD MILLION)

TABLE 26 ASIA PACIFIC URETHRITIS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 27 ASIA PACIFIC URETHRITIS MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 28 ASIA PACIFIC URETHRITIS MARKET, BY DRUG TREATMENT 2020-2027 (USD MILLION)

TABLE 29 ASIA PACIFIC URETHRITIS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 30 ASIA PACIFIC URETHRITIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 ASIA PACIFIC URETHRITIS MARKET BY REGION 2020-2027 (USD MILLION

TABLE 32 MIDDLE EAST & AFRICA URETHRITIS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA URETHRITIS MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA URETHRITIS MARKET, BY DRUG TREATMENT 2020-2027 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA URETHRITIS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA URETHRITIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA URETHRITIS MARKET BY REGION 2020-2027 (USD MILLION

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET DYNAMICS FOR GLOBAL URETHRITIS MARKET

FIGURE 3 GLOBAL URETHRITISMAKRET, BY SEGMENT, 2020

FIGURE 4 GLOBAL URETHRITISSUCCESS MARKET, BY REGION

FIGURE 5 GLOBAL URETHRITIS MARKET SHARE, BY TYPE 2020

FIGURE 6 GLOBAL URETHRITIS MARKET SHARE, BY DRUG TREATMENT 2020

FIGURE 7 GLOBAL URETHRITIS MARKET SHARE, BY DIAGNOSIS 2020

FIGURE 8 GLOBAL URETHRITIS MARKET SHARE, BY END USER, 2020

FIGURE 9 GLOBAL URETHRITIS MARKET SHARE, 2020

FIGURE 10 GLOBAL URETHRITIS MARKET SHARE, BY REGION, 2020

FIGURE 11 NORTH AMERICA URETHRITIS MARKET SHARE, BY COUNTRY, 2020

FIGURE 12 EUROPE URETHRITIS MARKET SHARE, BY COUNTRY, 2020

FIGURE 13 ASIA PACIFIC URETHRITIS MARKET SHARE, BY COUNTRY, 2020

FIGURE 14 MIDDLE EAST & AFRICA URETHRITIS MARKET, BY REGION, 2020

FIGURE 15 GLOBAL URETHRITIS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 16 F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS

FIGURE 17 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE

FIGURE 18 F. HOFFMANN-LA ROCHE AG: GEOGRAPHICAL REVENUE

FIGURE 19 ASTRAZENECA PLC.: KEY FINANCIALS

FIGURE 20 ASTRAZENECA PLC.SEGMENTAL REVENUE

FIGURE 21 ASTRAZENECA PLC.: GEOGRAPHICAL REVENUE

FIGURE 22 GLAXOSMITHKLINE: KEY FINANCIALS

FIGURE 23 GLAXOSMITHKLINE: SEGMENTAL REVENUE

FIGURE 24 GLAXOSMITHKLINE: GEOGRAPHICAL REVENUE

FIGURE 25 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 26 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 27 BRISTOL-MYERS SQUIBB COMPANY: GEOGRAPHICAL REVENUE

FIGURE 28 MERCK & CO.: FINANCIAL REVENUE

FIGURE 29 MERCK & CO.: SEGMENTAL REVENUE

FIGURE 30 MERCK & CO.: GEOGRPAHICAL REVENUE